[go: up one dir, main page]

WO1999009967B1 - Therapie hypocholesterolemiante - Google Patents

Therapie hypocholesterolemiante

Info

Publication number
WO1999009967B1
WO1999009967B1 PCT/US1998/017459 US9817459W WO9909967B1 WO 1999009967 B1 WO1999009967 B1 WO 1999009967B1 US 9817459 W US9817459 W US 9817459W WO 9909967 B1 WO9909967 B1 WO 9909967B1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
treatment
serum
prior
cholesterol
Prior art date
Application number
PCT/US1998/017459
Other languages
English (en)
Other versions
WO1999009967A2 (fr
WO1999009967A3 (fr
Inventor
Edwin J Whitney
Geraldine Mantell
Original Assignee
Merck & Co Inc
Edwin J Whitney
Geraldine Mantell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814415.7A external-priority patent/GB9814415D0/en
Priority claimed from GBGB9815851.2A external-priority patent/GB9815851D0/en
Application filed by Merck & Co Inc, Edwin J Whitney, Geraldine Mantell filed Critical Merck & Co Inc
Priority to EP98943329A priority Critical patent/EP1007019A2/fr
Priority to AU91153/98A priority patent/AU9115398A/en
Priority to CA002300165A priority patent/CA2300165A1/fr
Publication of WO1999009967A2 publication Critical patent/WO1999009967A2/fr
Publication of WO1999009967A3 publication Critical patent/WO1999009967A3/fr
Publication of WO1999009967B1 publication Critical patent/WO1999009967B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de prévention ou de réduction du risque d'un premier accident cardio-vasculaire, à l'aide d'un inhibiteur de HMG-CoA-réductase seul ou en combinaison avec un autre agent modifiant les lipides. Les sujets à traiter sont ceux qui présentent un taux de cholestérol total sérique moyen, un taux sérique de cholestérol dans les lipoprotéines de basse densité moyen à légèrement élevé et un taux sérique de cholestérol dans les lipoprotéines de haute densité en dessous de la moyenne, sans antécédents de maladies coronariennes cliniquement déclarées.
PCT/US1998/017459 1997-08-26 1998-08-21 Therapie hypocholesterolemiante WO1999009967A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98943329A EP1007019A2 (fr) 1997-08-26 1998-08-21 Therapie hypocholesterolemiante
AU91153/98A AU9115398A (en) 1997-08-26 1998-08-21 Cholesterol-lowering therapy
CA002300165A CA2300165A1 (fr) 1997-08-26 1998-08-21 Therapie hypocholesterolemiante

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US5696697P 1997-08-26 1997-08-26
US60/056,966 1997-08-26
US7685998P 1998-03-05 1998-03-05
US60/076,859 1998-03-05
US8536098P 1998-05-13 1998-05-13
US60/085,360 1998-05-13
GB9814415.7 1998-07-03
GBGB9814415.7A GB9814415D0 (en) 1998-07-03 1998-07-03 Cholesterol-lowering therapy
GB9815851.2 1998-07-21
GBGB9815851.2A GB9815851D0 (en) 1998-07-21 1998-07-21 Cholesterol-lowering therapy

Publications (3)

Publication Number Publication Date
WO1999009967A2 WO1999009967A2 (fr) 1999-03-04
WO1999009967A3 WO1999009967A3 (fr) 1999-05-20
WO1999009967B1 true WO1999009967B1 (fr) 1999-07-08

Family

ID=27517467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/017459 WO1999009967A2 (fr) 1997-08-26 1998-08-21 Therapie hypocholesterolemiante

Country Status (4)

Country Link
EP (1) EP1007019A2 (fr)
AU (1) AU9115398A (fr)
CA (1) CA2300165A1 (fr)
WO (1) WO1999009967A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7030106B2 (en) 2001-01-26 2006-04-18 Schering Corporation Sterol absorption inhibitor compositions
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368469B2 (en) 1999-08-30 2008-05-06 Sanofi-Aventis Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
CA2042526A1 (fr) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Methode permettant de prevenir une deuxieme crise cardiaque a l'aide d'un inhibiteur de la hmg coa-reductase
CA2070149A1 (fr) * 1991-06-04 1992-12-05 Stephen J. Boccuzzi Inhibiteurs de la reductase hmg-coa utilises pour la prevention de la restenose suivant une angioplastie coronarienne
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368469B2 (en) 1999-08-30 2008-05-06 Sanofi-Aventis Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7030106B2 (en) 2001-01-26 2006-04-18 Schering Corporation Sterol absorption inhibitor compositions
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7612058B2 (en) 2001-01-26 2009-11-03 Schering Corporation Methods for inhibiting sterol absorption
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368562B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7378518B2 (en) 2003-03-07 2008-05-27 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368563B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

Also Published As

Publication number Publication date
EP1007019A2 (fr) 2000-06-14
AU9115398A (en) 1999-03-16
CA2300165A1 (fr) 1999-03-04
WO1999009967A2 (fr) 1999-03-04
WO1999009967A3 (fr) 1999-05-20

Similar Documents

Publication Publication Date Title
WO1999009967B1 (fr) Therapie hypocholesterolemiante
AU5074196A (en) Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
Walker Simvastatin: the clinical profile
CA2088254A1 (fr) Traitement de l'hypercholesterolemie
WO1999066031A3 (fr) Preparation pharmaceutique a base d'un facteur vii
UA88265C2 (ru) Применение ингибитора ренин-ангиотензиновой системы для профилактики диабета
EP1238667A3 (fr) Utilisation des benzothiophènes pour le traitement de l'hypercholestérolemie
WO1999018952B1 (fr) REGULATION POSITIVE DE L'OXYDE NITRIQUE SYNTHASE DE CELLULES ENDOTHELIALES DE TYPE III PAR DES INHIBITEURS DE LA HMG-CoA REDUCTASE
CA2238098A1 (fr) Utilisation d'inhibiteurs de la nadph-oxydase pour la preparation d'un medicament destine a la prevention de l'atherosclerose
WO2000069445A8 (fr) Polytherapie pour traiter l'hypercholesterolemie
CA2248032A1 (fr) Agent abaissant le taux de cholesterol dans le serum
WO1998001100A3 (fr) Methode de traitement de l'hypercholesterolemie familiale homozygote
WO2002072104A3 (fr) Traitement combine a l'aide d'un agent antihypertenseur et d'un inhibiteur de l'absorption du cholesterol
WO2001070212A3 (fr) Methode et composition permettant de prevenir et de diminuer les symptomes de la menopause
EP1634605A3 (fr) traitement de la dyslipidémie chez un patient souffrant de diabète de type 2
WO1996001253A3 (fr) Inhibiteurs de pla2 et leur utilisation pour l'inhibition de l'absorption intestinale du cholesterol
WO2003099281A3 (fr) Procede de traitement du diabete
HK1042852A1 (zh) 增强胰岛素反应的方法
WO2001032160A3 (fr) Modification de la concentration de cholesterol au moyen de substances phytochimiques d'agrumes
CA2280773A1 (fr) Procedes d'administration d'amifostine
AU5544994A (en) Use of 17alpha-dihydroequilenin for lowering cholesterol
Schlueter et al. Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein (a) by fosinopril
Leon et al. Blood Lipid Effects of Antihypertensive Therapy: A Double‐Blind Comparison of the Effects of Methyldopa and Propranolol
WO1996013268A3 (fr) Utilisation d'un corticosteroide pour reduire les effets secondaires d'une emulsion perfluorochimique
WO1999043308A3 (fr) Traitement de l'hypertension arterielle pulmonaire par suppression de la tenascine et inhibition de l'elastase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2300165

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2300165

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1998943329

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 91153/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998943329

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998943329

Country of ref document: EP